We demonstrate that xylitol can be added to polymethylmethacrylate (PMMA) bone cement to enhance the elution of daptomycin in terms of both the peak and sustained release of antibiotic. We also demonstrate that a PMMA-xylitol formulation optimized for daptomycin can be used to enhance the elution of both vancomycin and gentamicin.
The treatment of chronic musculoskeletal and implant-associated infection requires a multifactorial approach that can include systemic antibiotic therapy, the surgical debridement of the affected site, including the removal of infected devices, and local antibiotic therapy targeted directly to the site of infection (1) . The latter often is done by incorporating antibiotics into handmade polymethylmethacrylate (PMMA) beads (8) . Elution profiles from antibiotic-laden PMMA beads can be modified by the incorporation of biologically inert fillers that increase both the rate and duration of antibiotic release (2) (3) (4) (5) . One such filler is glycine; indeed, PMMA beads containing glycine and gentamicin are commercially available in Europe under the trade name Septopal (Biomet Europe, Dordrecht, The Netherlands), and these beads exhibit an enhanced elution profile compared to that of handmade beads lacking glycine (6) . However, in previous studies we found that xylitol enhances elution to a greater extent than glycine (3). The experiments described in this report were aimed at optimizing the use of xylitol as a means of enhancing the elution of antibiotics from PMMA.
To evaluate the impact of xylitol on the elution of daptomycin from PMMA, a 40-g packet of Palacos-R PMMA (Zimmer, Inc., Dover, OH) powder was hand mixed with the designated amounts of daptomycin with or without xylitol crystals (Sigma Chemical Co., St. Louis, MO). Polymerization was done using a single vial of monomer irrespective of the presence or amount of xylitol. Each PMMA preparation was mixed until the cement was evenly thickened and then formed into beads using a 7-mm bead template (Wright Medical Technology, Arlington, TN). Beads prepared using each formulation were divided into sample sets of four beads per set. Each set was placed in a sterile 25-ml Erlenmeyer flask containing 6 ml of sterile phosphate-buffered saline (PBS). Each flask then was incubated at 37°C with constant shaking for 10 days. At 24-h intervals, the entire volume of PBS was removed for analysis and replaced with 6 ml of fresh, sterile PBS. Samples were stored at Ϫ20°C until the entire elution series for each PMMA formulation had been collected.
The amount of daptomycin in each sample was determined using a bioassay. Briefly, a fresh preparation of daptomycin was prepared in sterile PBS on each analysis day. This stock solution was used to prepare twofold dilutions in a 96-well microtiter plate. A twofold dilution series also was prepared with each experimental sample. Dilutions were prepared in tryptic soy broth (TSB) supplemented with 2.5 mM CaCl 2 . Each well was inoculated subsequently with 10 4 CFU of a daptomycin-sensitive strain of Staphylococcus aureus (UAMS-1; daptomycin MIC, Յ0.5 g/ml). After incubation at 37°C for 24 h, the concentration of active antibiotic in each experimental sample was assessed by comparison to the results obtained in the same assay with the daptomycin standard. Results obtained with the bioassay were confirmed by measuring the total amount of daptomycin in each sample by high-pressure liquid chromatography (HPLC) using a C 8 column and an acidic acetonitrile-salt mobile phase (7) .
We chose as our goal an elution profile that included a peak concentration at least 100ϫ and a sustained concentration (defined at 10 days postelution) at least 5ϫ the MIC defined by the CLSI as the breakpoint for a daptomycin-sensitive strain of S. aureus (Յ1.0 g/ml). Based on our earlier experiments demonstrating that the incorporation of 1.0 g of daptomycin and 28.0 g of xylitol failed to yield an elution profile that met either of these objectives (3), we initially used 2.0 g of daptomycin and 0, 7, 14, or 28 g of xylitol per 40-g packet of PMMA. Based on two-way analysis of variance with Tukey post hoc adjustments (SigmaStat, version 2; SPSS Inc., Chicago, IL), we confirmed a significant difference (P Յ 0.001) not only between PMMA and PMMA containing as little as 7 g of xylitol but also between PMMA formulations containing increasing amounts of xylitol. While all formulations, including the one that lacked xylitol, yielded a peak concentration of Ն100 g/ml, the only formulation that yielded a sustained concentration at least 5ϫ the MIC was the one containing 28 g of xylitol (Fig. 1) .
We next carried out an experiment using formulations containing 2.0 g of daptomycin and 18 or 22 g of xylitol per 40-g packet of PMMA. The results demonstrated that the 100ϫ elution objective was met with either formulation, but that 18 g of xylitol was not sufficient with respect to the 5ϫ objective (data not shown). In contrast, a PMMA formulation containing 2 g of daptomycin and 22 g of xylitol yielded a peak concentration of Ն640 g/ml and a sustained concentration of Ն6.11 g/ml (Fig. 2) . These results were confirmed by HPLC analysis (Fig. 2) .
Based on these results, we concluded that a PMMA formulation containing 2 g of daptomycin and 22 g of xylitol per 40-g packet of PMMA can be considered optimal, at least as defined by in vitro elution experiments. We therefore evaluated whether a PMMA formulation containing 22 g of xylitol could be used to enhance the elution of vancomycin and gentamicin. Zalavras et al. (8) recommended the use of 4.0 g of vancomycin or 3.6 g of gentamicin per 40-g packet of PMMA, and we based our experiments on these recommendations. With 4.0 g of vancomycin, xylitol was not necessary to achieve either of our elution objectives (Fig. 3) . However, subsequent experiments demonstrated that the inclusion of xylitol enhanced elution to the point that both also could be met with only 2.0 g of vancomycin. Specifically, a PMMA formulation containing 2 g of vancomycin and 22 g of xylitol yielded a peak concentration on day 1 of Ն240 g/ml and a sustained concentration on day 10 of Ն12.5 g/ml (Fig. 3) . These values represent 120ϫ and 6.25ϫ the vancomycin MICs defined for a sensitive strain (Յ2 g/ml).
Compared to results for the use of daptomycin and vancomycin, the inclusion of xylitol had relatively little impact on the elution of gentamicin from PMMA. Specifically, the peak concentration of Ն426.7 g/ml exceeded the 100ϫ MIC objective (400 g/ml) and was unchanged in the presence of xylitol. However, the sustained concentrations failed to achieve the 5ϫ objective (20 g/ml) irrespective of the inclusion of xylitol (Fig. 4) . Nevertheless, the addition of xylitol did enhance elution, as evidenced by the fact that a PMMA formulation containing 3.6 g of gentamicin but without xylitol fell below the 5ϫ objective by day 3 and reached undetectable levels by day 7 (Fig. 4) . In contrast, a formulation containing 3.6 g of gentamicin and 22 g of xylitol yielded an elution profile that met or exceeded the 5ϫ threshold through day 6 and yielded detectable levels of antibiotic (10 g/ml) even on day 10 (Fig. 4) . Moreover, this was true even when the amount of gentamicin was reduced from 3.6 to 2.0 g per 40 g of PMMA. In fact, PMMA formulations containing xylitol were the only ones in which the amount of antibiotic observed on day 10 remained above the CSLI breakpoint MIC (Յ4.0 g/ml) for a gentamicin-sensitive strain of S. aureus. Subsequent analysis confirmed that the differences observed in the elution profile of PMMA with and without xylitol were statistically significant (P Յ 0.001).
Taken together, the results we report demonstrate that the addition of 22 g of xylitol to a 40-g packet of PMMA enhances on September 7, 2017 by guest http://aac.asm.org/ the elution profiles of daptomycin and, to a somewhat lesser extent, vancomycin and gentamicin. This was true in terms of both peak and sustained concentrations of antibiotic. The inclusion of xylitol did not necessitate the alteration of the standard method for preparing PMMA beads, in that the single vial of monomer provided by the manufacturer remained sufficient to achieve polymerization. The verification of the significance of these in vitro observations will require in vivo studies taking into account both the complete resolution of the infection and the time required to achieve this outcome, but taken together we believe the results we report support the hypothesis that PMMA beads containing xylitol offer a therapeutic advantage over the current clinical practice.
